Inozyme raises $49M series A

Inozyme Pharma Inc. (Cambridge, Mass.) raised $49 million in a series A round led by Longitude Capital, with participation from New Enterprise Associates, Novo Ventures and Sanofi Ventures.

The newco, which spun out of Yale University last year, is developing enzyme replacement therapy INZ-701 to treat patients with calcification disorders caused by pyrophosphate deficiency...